Clinical experience with investigational myostatin inhibitors has thus far been limited to older patients with SMA (≥2 years of age), and the majority of the incident SMA population now receiving initial (and potentially additional) treatment are well below this age. The gene discussed is MSTN; the disease is proximal spinal muscular atrophy.